We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.
- Authors
Galani, I; Souli, M; Katsala, D; Karaiskos, I; Giamarellou, H; Antoniadou, A
- Abstract
Objectives To evaluate the in vitro activity of the combination of apramycin with colistin, meropenem, minocycline or sulbactam, against some well-characterized XDR Acinetobacter baumannii clinical isolates from Greece, to understand how apramycin can be best incorporated into clinical practice and optimize effectiveness. Methods In vitro interactions of apramycin (0.5×, 1× and 2× the MIC value) with colistin (2 mg/L), meropenem (30 mg/L), minocycline (3.5 mg/L) or sulbactam (24 mg/L) were tested using time–kill methodology. Twenty-one clinical A. baumannii isolates were chosen, exhibiting apramycin MICs of 4–16 mg/L, which were at or below the apramycin preliminary epidemiological cut-off value of 16 mg/L. These isolates were selected for a range of colistin (4–32 mg/L), meropenem (16–256 mg/L), minocycline (8–32 mg/L) and sulbactam (8–32 mg/L) MICs across the resistant range. Synergy was defined as a ≥2 log10 cfu/mL reduction compared with the most active agent. Results The combination of apramycin with colistin, meropenem, minocycline or sulbactam was synergistic, at least at one of the concentrations of apramycin (0.5×, 1× or 2× MIC), against 83.3%, 90.5%, 90.9% or 92.3% of the tested isolates, respectively. Apramycin alone was bactericidal at 24 h against 9.5% and 33.3% of the tested isolates at concentrations equal to 1× and 2× MIC, while the combination of apramycin at 2× MIC with colistin, meropenem or sulbactam was bactericidal against all isolates tested (100%). The apramycin 2× MIC/minocycline combination had bactericidal activity against 90.9% of the tested isolates. Conclusions Apramycin combinations may have potential as a treatment option for XDR/pandrug-resistant (PDR) A. baumannii infections and warrant validation in the clinical setting, when this new aminoglycoside is available for clinical use.
- Subjects
GREECE; MEROPENEM; ACINETOBACTER baumannii; COLISTIN; MINOCYCLINE
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2024, Vol 79, Issue 5, p1101
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkae077